PRGO Quote, Financials, Valuation and Earnings

Iterum Therapeutics PLC has a net margin of -1.93% compared to Perrigo Co PLC's net margin of --. Perrigo Co PLC's return on equity of -3.43% beat Iterum Therapeutics PLC's return on equity of --.

Perrigo Co PLC has a consensus price target of --, signalling upside risk potential of 39.9%. On the other hand Iterum Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 294.74%. Given that Iterum Therapeutics PLC has higher upside potential than Perrigo Co PLC, analysts believe Iterum Therapeutics PLC is more attractive than Perrigo Co PLC.

Perrigo Co PLC has a beta of 0.517, which suggesting that the stock is 48.32% less volatile than S&P 500. In comparison Iterum Therapeutics PLC has a beta of 2.404, suggesting its more volatile than the S&P 500 by 140.42%.

Perrigo Co PLC has a quarterly dividend of $0.28 per share corresponding to a yield of 4.31%. Iterum Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perrigo Co PLC pays -1178.74% of its earnings as a dividend. Iterum Therapeutics PLC pays out -- of its earnings as a dividend.

Perrigo Co PLC quarterly revenues are $1.1B, which are larger than Iterum Therapeutics PLC quarterly revenues of --. Perrigo Co PLC's net income of -$21M is lower than Iterum Therapeutics PLC's net income of -$7.1M. Notably, Perrigo Co PLC's price-to-earnings ratio is -- while Iterum Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perrigo Co PLC is 0.80x versus 36.27x for Iterum Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

Jazz Pharmaceuticals PLC has a net margin of -1.93% compared to Perrigo Co PLC's net margin of 20.39%. Perrigo Co PLC's return on equity of -3.43% beat Jazz Pharmaceuticals PLC's return on equity of 12.28%.

Perrigo Co PLC has a consensus price target of --, signalling upside risk potential of 39.9%. On the other hand Jazz Pharmaceuticals PLC has an analysts' consensus of $181.05 which suggests that it could grow by 45.31%. Given that Jazz Pharmaceuticals PLC has higher upside potential than Perrigo Co PLC, analysts believe Jazz Pharmaceuticals PLC is more attractive than Perrigo Co PLC.

Perrigo Co PLC has a beta of 0.517, which suggesting that the stock is 48.32% less volatile than S&P 500. In comparison Jazz Pharmaceuticals PLC has a beta of 0.568, suggesting its less volatile than the S&P 500 by 43.191%.

Perrigo Co PLC has a quarterly dividend of $0.28 per share corresponding to a yield of 4.31%. Jazz Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perrigo Co PLC pays -1178.74% of its earnings as a dividend. Jazz Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Perrigo Co PLC quarterly revenues are $1.1B, which are larger than Jazz Pharmaceuticals PLC quarterly revenues of $1.1B. Perrigo Co PLC's net income of -$21M is lower than Jazz Pharmaceuticals PLC's net income of $215.1M. Notably, Perrigo Co PLC's price-to-earnings ratio is -- while Jazz Pharmaceuticals PLC's PE ratio is 17.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perrigo Co PLC is 0.80x versus 2.07x for Jazz Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Mallinckrodt PLC has a net margin of -1.93% compared to Perrigo Co PLC's net margin of -5.18%. Perrigo Co PLC's return on equity of -3.43% beat Mallinckrodt PLC's return on equity of -287.81%.

Perrigo Co PLC has a consensus price target of --, signalling upside risk potential of 39.9%. On the other hand Mallinckrodt PLC has an analysts' consensus of -- which suggests that it could fall by --. Given that Perrigo Co PLC has higher upside potential than Mallinckrodt PLC, analysts believe Perrigo Co PLC is more attractive than Mallinckrodt PLC.

Perrigo Co PLC has a beta of 0.517, which suggesting that the stock is 48.32% less volatile than S&P 500. In comparison Mallinckrodt PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Perrigo Co PLC has a quarterly dividend of $0.28 per share corresponding to a yield of 4.31%. Mallinckrodt PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perrigo Co PLC pays -1178.74% of its earnings as a dividend. Mallinckrodt PLC pays out -- of its earnings as a dividend.

Perrigo Co PLC quarterly revenues are $1.1B, which are larger than Mallinckrodt PLC quarterly revenues of $505.5M. Perrigo Co PLC's net income of -$21M is higher than Mallinckrodt PLC's net income of -$26.2M. Notably, Perrigo Co PLC's price-to-earnings ratio is -- while Mallinckrodt PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perrigo Co PLC is 0.80x versus 0.00x for Mallinckrodt PLC. Usually stocks with elevated PS ratios are considered overvalued.

Medtronic PLC has a net margin of -1.93% compared to Perrigo Co PLC's net margin of 15.11%. Perrigo Co PLC's return on equity of -3.43% beat Medtronic PLC's return on equity of 8.54%.

Perrigo Co PLC has a consensus price target of --, signalling upside risk potential of 39.9%. On the other hand Medtronic PLC has an analysts' consensus of $96.00 which suggests that it could grow by 18.9%. Given that Perrigo Co PLC has higher upside potential than Medtronic PLC, analysts believe Perrigo Co PLC is more attractive than Medtronic PLC.

Perrigo Co PLC has a beta of 0.517, which suggesting that the stock is 48.32% less volatile than S&P 500. In comparison Medtronic PLC has a beta of 0.820, suggesting its less volatile than the S&P 500 by 17.999%.

Perrigo Co PLC has a quarterly dividend of $0.28 per share corresponding to a yield of 4.31%. Medtronic PLC offers a yield of 3.46% to investors and pays a quarterly dividend of $0.70 per share. Perrigo Co PLC pays -1178.74% of its earnings as a dividend. Medtronic PLC pays out 99.73% of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Perrigo Co PLC quarterly revenues are $1.1B, which are smaller than Medtronic PLC quarterly revenues of $8.4B. Perrigo Co PLC's net income of -$21M is lower than Medtronic PLC's net income of $1.3B. Notably, Perrigo Co PLC's price-to-earnings ratio is -- while Medtronic PLC's PE ratio is 24.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perrigo Co PLC is 0.80x versus 3.20x for Medtronic PLC. Usually stocks with elevated PS ratios are considered overvalued.